Organogenesis Publishes Randomized Clinical Trial Results Demonstrating Safety And Efficacy Of NuShield For Diabetic Foot Ulcers
Portfolio Pulse from Benzinga Newsdesk
Organogenesis has published results from a 218-patient randomized clinical trial showing that its product, NuShield, is safe and effective for treating diabetic foot ulcers. The study demonstrated a statistically significant improvement in wound closure at 12 weeks compared to standard care. Organogenesis believes this study meets the requirements for Medicare coverage under proposed Local Coverage Determinations.
October 01, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Organogenesis' NuShield product demonstrated superior efficacy in a clinical trial for diabetic foot ulcers, which may lead to Medicare coverage.
The positive clinical trial results for NuShield could enhance Organogenesis' market position and lead to increased sales if Medicare coverage is approved. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100